Rash was totally absent in 14 of 15 individuals receiving canakinumab, as compared with 5 of 16 sufferers receiving placebo . At the final end of part 2, 6 of 15 individuals in the canakinumab group reported having a complete lack of symptoms, as compared with no individuals in the placebo group . Four sufferers in the canakinumab group reported having serious symptoms associated with various other disorders: two individuals in a single household had severe gastroenteritis, a third patient had unpleasant fibromyalgia, and a fourth had migraine . No serious symptoms had been reported by the individuals in the placebo group at the end of part 2 .Three various other patients with BRAF mutations got increased uptake on the post-selumetinib iodine-124 PET study also, even though the threshold necessary for therapy was not reached. The differences noticed between BRAF-mutant and RAS-mutant tumors remain to be explained, but it is possible that MAPK signaling is certainly incompletely inhibited in a few BRAF-mutant tumors due to higher flux through the pathway.